Pharmaceuticals, Biotechnology and Life Sciences
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov.…
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United…
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift…
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (NASDAQ: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company…
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) — Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG),…
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative…
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing,…
Actionable offering helps enable earlier, more personalized breast cancer interventionsBOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025…
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology…
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on…